{"id":"bxcl701","safety":{"commonSideEffects":[{"rate":null,"effect":"Lymphopenia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"S1P1 inhibition prevents lymphocyte egress from secondary lymphoid organs, reducing circulating lymphocyte counts and dampening aberrant immune responses. This mechanism is thought to be beneficial in autoimmune and inflammatory conditions by sequestering autoreactive lymphocytes in lymph nodes and spleen, thereby reducing their infiltration into affected tissues.","oneSentence":"BXCL701 is a selective inhibitor of sphingosine-1-phosphate receptor 1 (S1P1) that modulates immune cell trafficking and reduces pathological inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:23:00.362Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Systemic lupus erythematosus (SLE)"}]},"trialDetails":[{"nctId":"NCT05558982","phase":"PHASE2","title":"BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Georgetown University","startDate":"2023-08-16","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":22},{"nctId":"NCT03910660","phase":"PHASE1, PHASE2","title":"A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.","status":"COMPLETED","sponsor":"BioXcel Therapeutics Inc","startDate":"2019-02-12","conditions":"Prostate Cancer, Neuroendocrine Tumors, Small Cell Carcinoma","enrollment":98},{"nctId":"NCT05703542","phase":"PHASE1","title":"BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"Eric Stephen Winer, MD","startDate":"2023-02-02","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2","enrollment":24},{"nctId":"NCT04171219","phase":"PHASE2","title":"Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-03-19","conditions":"Advanced Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm","enrollment":31},{"nctId":"NCT00489710","phase":"PHASE2","title":"Talabostat in Treating Patients With Metastatic Kidney Cancer","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2006-12","conditions":"Kidney Cancer","enrollment":""},{"nctId":"NCT04123574","phase":"EARLY_PHASE1","title":"A Pilot Study of BXCL701 in Patients With Pancreatic Cancer","status":"WITHDRAWN","sponsor":"BioXcel Therapeutics Inc","startDate":"2019-10-15","conditions":"Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic","enrollment":""},{"nctId":"NCT02083120","phase":"NA","title":"Efficacy and Physiology of Nasal High Flow Therapy","status":"COMPLETED","sponsor":"Institut für Pneumologie Hagen Ambrock eV","startDate":"2014-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":46},{"nctId":"NCT00086203","phase":"PHASE2","title":"Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","sponsor":"Point Therapeutics","startDate":"","conditions":"Chronic Lymphocytic Leukemia","enrollment":""},{"nctId":"NCT00303940","phase":"PHASE1","title":"Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2005-12","conditions":"Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Kidney Cancer","enrollment":26},{"nctId":"NCT00116389","phase":"PHASE2","title":"Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas","status":"TERMINATED","sponsor":"Point Therapeutics","startDate":"","conditions":"Pancreatic Cancer, Neoplasm Metastasis, Adenocarcinoma","enrollment":60},{"nctId":"NCT00083239","phase":"PHASE2","title":"Study of Talabostat in Advanced Melanoma","status":"COMPLETED","sponsor":"Point Therapeutics","startDate":"","conditions":"Melanoma, Skin Cancer","enrollment":""},{"nctId":"NCT00243204","phase":"PHASE3","title":"Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy","status":"TERMINATED","sponsor":"Point Therapeutics","startDate":"2006-01","conditions":"Carcinoma, Non-Small Cell Lung","enrollment":400},{"nctId":"NCT00083252","phase":"PHASE2","title":"Study of Talabostat and Cisplatin in Advanced Melanoma","status":"COMPLETED","sponsor":"Point Therapeutics","startDate":"","conditions":"Melanoma, Skin Cancer","enrollment":""},{"nctId":"NCT00080080","phase":"PHASE2","title":"Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Point Therapeutics","startDate":"","conditions":"Lung Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Talabostat"],"phase":"phase_2","status":"active","brandName":"BXCL701","genericName":"BXCL701","companyName":"Eric Stephen Winer, MD","companyId":"eric-stephen-winer-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BXCL701 is a selective inhibitor of sphingosine-1-phosphate receptor 1 (S1P1) that modulates immune cell trafficking and reduces pathological inflammation. Used for Systemic lupus erythematosus (SLE).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}